News & Events

GenFleet Therapeutics: First China-developed KRAS G12C Inhibitor Launched in Macau

GenFleet Therapeutics: First China-developed KRAS G12C Inhibitor Launched in Macau

Sosimerasib for Patients With Locally Advanced or Metastatic KRAS G12C-Mutated Non-Small Cell Lung Cancer

Sosimerasib for Patients With Locally Advanced or Metastatic KRAS G12C-Mutated Non-Small Cell Lung Cancer

Targeting KRAS: Emerging Frontline Options for Patients With NSCLC

Targeting KRAS: Emerging Frontline Options for Patients With NSCLC

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis

KRAS G12C-Mutated NSCLC: Current Treatment Paradigms

KRAS G12C-Mutated NSCLC: Current Treatment Paradigms

Evaluating Efficacy Outcomes of TKI Therapies in KRAS G12C-Mutated NSCLC

Evaluating Efficacy Outcomes of TKI Therapies in KRAS G12C-Mutated NSCLC

Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody

Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC